Eflucimibe
Eflucimibe has been in phase II clinical trials for the treatment of atherosclerosis and hyperlipidemia. However, this research has been discontinued.
The compound was codeveloped by Pierre Fabre and Lilly.
General Information
Update Date：2016-04-26
- Drug Name：
- Eflucimibe
- Research Code：
- F-12511; L-0081
- Trade Name：
- MOA：
- ACAT inhibitor
- Indication：
- Atherosclerosis; Hyperlipidemia
- Status：
- Phase Ⅱ (Discontinued)
- Company：
- Pierre Fabre (Originator) , Lilly
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-01-06
|
Molecular Weight | 469.72 | ||||||||||||
| Formula | C29H43NO2S | |||||||||||||
| CAS No. | 202340-45-2 (Eflucimibe); | |||||||||||||
| Chemical Name | Benzeneacetamide, a-(dodecylthio)-N-(4-hydroxy-2,3,5-trimethylphenyl)-, (aS)- | |||||||||||||
| Eflucimibe （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||